This week, key news includes Xiaomi's launch of an electric SUV aimed at competing with Tesla's Model Y. The Federal Circuit has reversed a PTAB ruling regarding X-ray imaging patents due to incorrect claim interpretation. Other highlights involve ongoing federal efforts to remove certain drug device patents, the approval of a new Copyright Restatement by the American Law Institute, and a report from the European Patent Office on its economic impact. The U.S. Patent and Trademark Office is also hosting discussions on counterfeiting in e-commerce platforms.
On Friday, May 23, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc., reversing the Patent Trial and Appeal Board's determination that Carl Zeiss did not prove that patent claims to X-ray imaging systems incorporating projection magnification were invalid as anticipated by a scientific paper describing the use of X-ray beams to image rodent organs.
The Federal Circuit determined that the PTAB arrived at an improper construction for the claim limitation "between 1 and 10" that excluded small amounts of magnification of the projection X-ray stage that were nonetheless magnified between 1 and 10 times.
Collection
[
|
...
]